Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
2023 · Nature Medicine · 385 citations
https://doi.org/10.1038/s41591-023-02453-x
J
John Lenehan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
41
Papers
936
Citations
12
h-index
16
i10-index
John Lenehan is an academic researcher from Ontario Institute for Cancer Research. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Gut microbiota and health & Clostridium difficile and Clostridium perfringens research. The author has an h-index of 12, co-authored 35 publications.
ORCID: 0000-0002-6225-3973Papers by this author
worksOATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
2015 · British Journal of Cancer · 74 citations
https://doi.org/10.1038/bjc.2015.5
1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)
2024 · Annals of Oncology · 17 citations
https://doi.org/10.1016/j.annonc.2024.08.1126
Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma
2022 · Current Oncology · 1 citations
https://doi.org/10.3390/curroncol29030126
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat